Although DON, a selective AChE inhibitor, is commonly used to treat mild, moderate, and severe degrees of AD, as well as vascular dementia and dementia linked to Parkinson’s disease (Jiang et al. 2019), the results of the current investigation showed that PTX revealed better outcomes than DON in modulating AChE activity, Bax, CAS-9, BACE1, CLU, and p-tau. This evidence concerns the gene BACE1 and Parkinson disease.